microRNA-450b-3p (miR-450b-3p)

microRNA-450b-3p (miR-450b-3p) is a short, single-stranded, non-coding RNA molecule of approximately 22 nucleotides, part of the microRNA family[7][5]. It functions primarily as a post-transcriptional regulator of gene expression by binding to complementary sequences in the 3′ untranslated region (UTR) of specific target mRNAs, leading to translational inhibition or mRNA degradation[7][1][2][4]. miR-450b-3p has been characterized as a tumor suppressor in several cancers, including breast, gastric, and hepatocellular carcinoma, where its expression is commonly downregulated[1][2][4]. In breast cancer, miR-450b-3p directly represses HER3 (ERBB3), inhibiting the proliferative PI3K/AKT pathway and improving drug sensitivity to anti-HER3 therapies and chemotherapeutics such as trastuzumab and doxorubicin[1]. In hepatocellular carcinoma, miR-450b-3p targets phosphoglycerate kinase 1 (PGK1), inhibiting cell growth and division[2]. Its expression levels can serve as a biomarker for disease prognosis and therapy response, but it is not itself a protein or typical receptor/target for direct pharmacological intervention; rather, it is a regulatory nucleic acid molecule commonly investigated for its utility in diagnostics, prognostics, and possible RNA-based therapies[1][2][4][5]. Please note: miR-450b-3p is a non-coding RNA and not a typical "therapeutic target" like a receptor or enzyme. It is not directly “druggable” but is medically relevant as a regulator of disease-associated genes.

Other names

hsa-miR-450b-3pMIR450B-3pmiRNA-450b-3p

Not a direct drug target; acts by binding complementary sequences in the 3′ UTR of specific mRNAs (e.g., HER3, PGK1), leading to degradation or translational repression of the mRNA[1][2][4]. Functions primarily as a **tumor suppressor** by inhibiting key oncogenic pathways (e.g., downregulation of HER3/PI3K/AKT in breast cancer[1], PGK1 in hepatocellular carcinoma[2]).